ArticleOpen veterinary journal2026
Successful management of recurrent feline hepatic lipidosis with equine placenta extract supplementation: A case report.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic lipidosis (HL) is a common and life-threatening hepatopathy in cats, for which novel therapeutic options remain limited. Case Description: A 14-year-old neutered male Egyptian Mau cat presented with a 1-week history of anorexia, intermittent vomiting, and jaundice. Plasma biochemistry revealed markedly elevated levels of alanine aminotransferase (ALT: 7270 U/L), aspartate aminotransferase (AST: 2754 U/L), and total bilirubin (5.5 mg/dl). Histopathological examination revealed multifocal hepatocellular vacuolar degeneration and random hepatocellular necrosis, consistent with HL, potentially associated with chronic enteropathy and a suspected early neoplastic lymphoid process. Standard therapy with hepatoprotective agents and nutritional support led to limited improvement; therefore, 2 ml of equine placental extract (EPE; Japan Bio Products Co., Ltd., Japan) was administered orally once daily. The cat remained clinically stable with continued administration of EPE and ursodeoxycholic acid. Conclusion: EPE may represent a potential novel adjunctive therapy for feline hepatic lipidosis and was temporally associated with biochemical improvement, indicating hepatocellular recovery and appetite restoration in this case.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.